Update in lung cancer and mesothelioma 2009. (Q37728779)

22 August 2017

1 reference

title

Update in lung cancer and mesothelioma 2009. (English)

1 reference

22 August 2017

1 reference

Jean-Paul Sculier

1

1 reference

22 August 2017

Thierry Berghmans

series ordinal

2

1 reference

22 August 2017

Anne-Pascale Meert

series ordinal

3

1 reference

22 August 2017

language of work or name

English

0 references

publication date

1 April 2010

1 reference

American Journal of Respiratory and Critical Care Medicine

22 August 2017

published in

1 reference

22 August 2017

volume

181

1 reference

22 August 2017

issue

8

1 reference

22 August 2017

page(s)

773-781

1 reference

A small-cell lung cancer genome with complex signatures of tobacco exposure

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201001-0045UP

Inhibition of nonneuronal alpha7-nicotinic receptor for lung cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201001-0045UP

A meta-analysis of TP53 codon 72 polymorphism and lung cancer risk: evidence from 15,857 subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201001-0045UP

The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201001-0045UP

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201001-0045UP

Incidence of human papilloma virus in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201001-0045UP

Human papillomavirus type 16 and 18 in primary lung cancers--a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201001-0045UP

High dietary inorganic phosphate increases lung tumorigenesis and alters Akt signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201001-0045UP

Green tea, black tea consumption and risk of lung cancer: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201001-0045UP

Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201001-0045UP

Association between estrogen receptor-beta expression and epidermal growth factor receptor mutation in the postoperative prognosis of adenocarcinoma of the lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201001-0045UP

Evolution of microRNA expression during human bronchial squamous carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201001-0045UP

Claudin-1 is a metastasis suppressor and correlates with clinical outcome in lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201001-0045UP

Fragile histidine triad gene inactivation in lung cancer: the European Early Lung Cancer project

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201001-0045UP

Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201001-0045UP

Nuclear survivin in pN2 nonsmall cell lung cancer: prognostic and clinical implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201001-0045UP

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201001-0045UP

Genome-wide analysis of survival in early-stage non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201001-0045UP

Prognostic value of vascular endothelial growth factor expression in patients with lung cancer: a systematic review with meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201001-0045UP

A randomized study of lung cancer screening with spiral computed tomography: three-year results from the DANTE trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201001-0045UP

The Danish randomized lung cancer CT screening trial--overall design and results of the prevalence round.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201001-0045UP

Effect of CT screening on smoking habits at 1-year follow-up in the Danish Lung Cancer Screening Trial (DLCST).

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201001-0045UP

Management of lung nodules detected by volume CT scanning.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201001-0045UP

Plasma DNA quantification in lung cancer computed tomography screening: five-year results of a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201001-0045UP

The International Association for the Study of Lung Cancer Staging Project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201001-0045UP

The IASLC Lung Cancer Staging Project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201001-0045UP

The IASLC lung cancer staging project: a proposal for a new international lymph node map in the forthcoming seventh edition of the TNM classification for lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201001-0045UP

The IASLC Lung Cancer Staging Project: data elements for the prospective project

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201001-0045UP

Evaluation of the new TNM staging system proposed by the International Association for the Study of Lung Cancer at a single institution

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201001-0045UP

Prognostic significance of visceral pleural invasion in the forthcoming (seventh) edition of TNM classification for lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201001-0045UP

Application of the revised lung cancer staging system (IASLC Staging Project) to a cancer center population

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201001-0045UP

Revisiting stage IIIB and IV non-small cell lung cancer: analysis of the surveillance, epidemiology, and end results data

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201001-0045UP

Visceral pleura invasion impact on non-small cell lung cancer patient survival: its implications for the forthcoming TNM staging based on a large-scale nation-wide database.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201001-0045UP

Number of metastatic sites is a strong predictor of survival in patients with nonsmall cell lung cancer with or without brain metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201001-0045UP

TNM stage is the most important determinant of survival in metachronous lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201001-0045UP

Positron emission tomography in staging early lung cancer: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201001-0045UP

Preoperative staging of lung cancer with combined PET-CT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201001-0045UP

Efficacy comparison between (18)F-FDG PET/CT and bone scintigraphy in detecting bony metastases of non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201001-0045UP

Hospital characteristics associated with timeliness of care in veterans with lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201001-0045UP

Timeliness of care in patients with lung cancer: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201001-0045UP

Lung cancer diagnostic and treatment intervals in the United States: a health care disparity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201001-0045UP

The clinical impact of integrated FDG PET-CT on management decisions in patients with lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201001-0045UP

ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy).

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201001-0045UP

Improvements in surgical results for lung cancer from 1989 to 1999 in Japan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201001-0045UP

Risk factors for morbidity after lobectomy for lung cancer in elderly patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201001-0045UP

The perioperative complications for elderly patients with lung cancer associated with a pulmonary resection under general anesthesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201001-0045UP

Pulmonary resection in patients aged 80 years or over with clinical stage I non-small cell lung cancer: prognostic factors for overall survival and risk factors for postoperative complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201001-0045UP

Validation of a model to predict perioperative mortality from lung cancer resection in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201001-0045UP

Systematic review and meta-analysis of randomized and nonrandomized trials on safety and efficacy of video-assisted thoracic surgery lobectomy for early-stage non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201001-0045UP

Lobectomy by video-assisted thoracic surgery (VATS) versus thoracotomy for lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201001-0045UP

Robot-assisted lobectomy for early-stage lung cancer: report of 100 consecutive cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201001-0045UP

Limited resection for noninvasive bronchioloalveolar carcinoma diagnosed by intraoperative pathologic examination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201001-0045UP

Stereotactic radiosurgery for the treatment of stage I non-small cell lung cancer in high-risk patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201001-0045UP

Magnitude of benefit of adjuvant chemotherapy for non-small cell lung cancer: meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201001-0045UP

Preoperative versus postoperative chemotherapy in patients with resectable non-small cell lung cancer: systematic review and indirect comparison meta-analysis of randomized trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201001-0045UP

Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201001-0045UP

Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201001-0045UP

Screening for epidermal growth factor receptor mutations in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201001-0045UP

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201001-0045UP

Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201001-0045UP

Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201001-0045UP

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201001-0045UP

Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201001-0045UP

A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201001-0045UP

Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201001-0045UP

Global Lung Oncology Branch trial 3 (GLOB3): final results of a randomised multinational phase III study alternating oral and i.v. vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small-cell lung can

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201001-0045UP

Quality of life and disease-related symptoms in previously treated Japanese patients with non-small-cell lung cancer: results of a randomized phase III study (V-15-32) of gefitinib versus docetaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201001-0045UP

Phase III trial of docetaxel plus gemcitabine versus docetaxel in second-line treatment for non-small-cell lung cancer: results of a Japan Clinical Oncology Group trial (JCOG0104).

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201001-0045UP

Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201001-0045UP

Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201001-0045UP

Multicenter randomized open-label phase III study comparing efficacy, safety, and tolerability of conventional carboplatin plus etoposide versus dose-intensified carboplatin plus etoposide plus lenograstim in small-cell lung cancer in "extensive dis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201001-0045UP

Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201001-0045UP

Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201001-0045UP

Plasmablastic lymphoma in an immunocompetent patient.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201001-0045UP

Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201001-0045UP

Clinical impact and reliability of pleural fluid mesothelin in undiagnosed pleural effusions

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201001-0045UP

Kinetics of soluble mesothelin in patients with malignant pleural mesothelioma during treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201001-0045UP

10.1164/RCCM.201001-0045UP

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference